PCM
CLDX icon

Prelude Capital Management’s Celldex Therapeutics CLDX Stock Holding History

Prelude Capital Management’s Portfolio CLDX Stock Details CLDX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-31,066
Closed -$632K – 1175
2025
Q2 		$632K Buy
+31,066
New +$605K 0.06% 374
2024
Q2 		– Sell
-16,300
Closed -$684K – 1251
2024
Q1 		$684K Sell
16,300
-10,212
-39% -$419K 0.04% 502
2023
Q4 		$1.05M Buy
+26,512
New +$780K 0.07% 290
2017
Q4 		– Sell
-1,220
Closed -$52K – 1393
2017
Q3 		$52K Buy
+1,220
New +$45.7K ﹤0.01% 1093
2015
Q3 		– Sell
-926
Closed -$350K – 1515
2015
Q2 		$350K Hold
926
– – 0.05% 404
2015
Q1 		$387K Buy
+926
New +$331K 0.05% 418

Other funds holding CLDX

KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Prelude Capital Management's CLDX Position: Q3 2025 in Review

Prelude Capital Management sold out of Celldex Therapeutics (CLDX) in Q3 2025, closing a stake of 31,066 shares — an estimated $632K sold.

Prelude Capital Management first reported a position in CLDX in Q1 2015 and held it in 6 quarters. The position peaked at $1.05M in Q4 2023. 184 funds tracked by Wall St. Rank hold CLDX as of Q3 2025.

  • Prelude Capital Management reported no remaining Celldex Therapeutics position as of Q3 2025 after selling out during the quarter.
  • Prelude Capital Management sold 31,066 Celldex Therapeutics shares in Q3 2025, an estimated $632K.
  • Prelude Capital Management first reported a position in Celldex Therapeutics in Q1 2015 and held it in 6 quarters.
  • Prelude Capital Management's Celldex Therapeutics position peaked at $1.05M in Q4 2023.
  • 184 funds tracked by Wall St. Rank held Celldex Therapeutics as of Q3 2025.

Based on Prelude Capital Management's 13F filing for Q3 2025, filed 14 Nov 2025.